AIM (AIM ImmunoTech) Cyclically Adjusted Book per Share: $704.75 (As of Mar. 2026)


AIM AIM ImmunoTech Inc AIM
33 GF Score
Price $0.29
GF Value $2.69
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is AIM ImmunoTech Cyclically Adjusted Book per Share?

AIM ImmunoTech AIM -7.07% 33 Cyclically Adjusted Book per Share is $704.75 as of Mar. 2026. GuruFocus rates AIM with a GF Score™ of 33/100 and a GF Value™ of $2.69 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

AIM ImmunoTech's adjusted book value per share for the three months ended in Mar. 2026 was $0.258. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $704.75 for the trailing ten years ended in Mar. 2026.

During the past 12 months, AIM ImmunoTech's average Cyclically Adjusted Book Growth Rate was -44.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -40.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -33.80% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -24.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of AIM ImmunoTech was 12.80% per year. The lowest was -40.30% per year. And the median was -9.20% per year.

As of today (2026-06-29), AIM ImmunoTech's current stock price is $0.29005. AIM ImmunoTech's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $704.75. AIM ImmunoTech's Cyclically Adjusted PB Ratio of today is 0.00.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of AIM ImmunoTech was 0.64. The lowest was 0.01. And the median was 0.03.


AIM ImmunoTech  (AMEX:AIM) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

AIM ImmunoTech's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.29005/704.75
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of AIM ImmunoTech was 0.64. The lowest was 0.01. And the median was 0.03.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


AIM ImmunoTech Cyclically Adjusted Book per Share Related Terms


AIM ImmunoTech Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for AIM ImmunoTech's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech Cyclically Adjusted Book per Share Chart

AIM ImmunoTech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,117.52 3,833.43 2,444.41 1,487.88 816.85

AIM ImmunoTech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,279.22 1,109.17 958.68 816.85 704.75

AIM vs RVPH, BOLT, ERNA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, AIM ImmunoTech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Cyclically Adjusted PB Ratio falls into.


AIM
33GF Score
AIM ImmunoTech Inc AIM
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AIM ImmunoTech Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AIM ImmunoTech's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.258/330.2130*330.2130
=0.258

Current CPI (Mar. 2026) = 330.2130.

AIM ImmunoTech Quarterly Data

Book Value per Share CPI Adj_Book
201606 3,497.800 241.018 4,792.252
201609 3,326.200 241.428 4,549.408
201612 2,583.000 241.432 3,532.838
201703 2,158.000 243.801 2,922.874
201706 1,476.000 244.955 1,989.730
201709 1,434.429 246.819 1,919.087
201712 1,243.286 246.524 1,665.352
201803 1,133.333 249.554 1,499.641
201806 826.909 251.989 1,083.603
201809 585.364 252.439 765.709
201812 470.364 251.233 618.232
201903 100.786 254.202 130.923
201906 242.136 256.143 312.156
201909 214.115 256.759 275.369
201912 121.769 256.974 156.474
202003 122.214 258.115 156.351
202006 134.854 257.797 172.735
202009 148.351 260.280 188.210
202012 143.512 260.474 181.936
202103 146.643 264.877 182.815
202106 135.296 271.696 164.436
202109 128.021 274.310 154.111
202112 117.008 278.802 138.584
202203 109.554 287.504 125.828
202206 99.931 296.311 111.364
202209 87.281 296.808 97.104
202212 78.528 296.797 87.369
202303 70.715 301.836 77.363
202306 60.711 305.109 65.706
202309 44.902 307.789 48.173
202312 19.400 306.746 20.884
202403 8.225 312.332 8.696
202406 10.668 314.175 11.213
202409 4.961 315.301 5.196
202412 -2.015 315.605 -2.108
202503 -5.327 319.799 -5.500
202506 -8.557 322.561 -8.760
202509 -2.196 324.800 -2.233
202512 -3.184 324.054 -3.245
202603 0.258 330.213 0.258

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $704.75 mean?
AIM ImmunoTech (AIM) has a Cyclically Adjusted Book per Share of $704.75 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on AIM ImmunoTech and its competitors.
Is AIM ImmunoTech's Cyclically Adjusted Book per Share too high?
AIM ImmunoTech's current Cyclically Adjusted Book per Share is $704.75. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Cyclically Adjusted Book per Share compare to RVPH and BOLT?
AIM ImmunoTech's Cyclically Adjusted Book per Share of $704.75 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current Cyclically Adjusted Book per Share is $704.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.69, compared to a current price of $0.29 — trading 89.2% below its estimated fair value. The current Cyclically Adjusted Book per Share is $704.75. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current Cyclically Adjusted Book per Share is $704.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AIM ImmunoTech (AIM) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of $0.29 is trading 89.2% below its estimated GF Value™ of $2.69. GuruFocus considers AIM ImmunoTech to be Possible Value Trap.

Key valuation signals for AIM:

  • Cyclically Adjusted Book per Share: $704.75
  • GF Value™: $2.69 vs. price of $0.29 (89.2% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AIM ImmunoTech Business Description

Other Exchanges 0A4Y:UK
Address 2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score

Get the complete analysis for AIM

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.29
Price
$2.69
GF Value